regeneron glp 1 Announcing an in-licensing agreement for an investigational, novel dual GLP- 1/GIP receptor agonist that will enable synergy and flexibility across our broad pipeline of obesity and metabolic programs focused on improved quality of Regeneron's obesity drug shows Zepbound-like

In an interview with Hunterbrook Media, Upadhye said that even with a green light from the FDA to sell compounded drugs, Hims could still face future patent litigation

Links Mentioned in This Episode: McCall McPhersons Instagram: @mccallmcphersonpa McCall McPhersons Tik Tok: @mccallmcpherson McCall McPhersons Youtube Modern Thyroid Clinic Personalized care for thyroid and metabolic health

Knowledgeable coaches who can promote appropriate behavior change and medication adherence can be essential to long-term success for these patients

Retatrutide goes further as a triple agonist, additionally targeting the glucagon receptor, which may contribute to its even greater weight loss efficacy by increasing energy expenditure and fat oxidation

Pyke C, Heller RS, Kirk RK et al